In 4 months, a large number of presidents and vice presidents of pharmaceutical companies have resigned or replaced!

Since the beginning of this year, the mobility of talents in the pharmaceutical industry is still relatively high.
In the first two months of 2022 alone, nearly 90 pharmaceutical companies in the A-share market have announced more than 120 resignation information, and the executives that investors focus on include the chairman, Presidents, vice presidents, core technical backbones, etc.
"run away" more frequently
.
The president plays an important role in a pharmaceutical company, including mastering national policies, laws and regulations, mobilizing the enthusiasm of employees, establishing a reasonable organizational structure, coordinating various internal and external relations, and overseeing the overall situation
.
In the first four months of 2022, a large number of presidents and vice presidents of pharmaceutical companies have resigned or been replaced
.
For example, on April 20, Merck announced that Joseph Romanelli would return to Merck to lead Merck's Human Health International Department and join the company's executive committee, reporting directly to Merck's global president and CEO Dai Fucai (Robert Davis), personnel appointment effective August 1, 2022
.
On April 14, Jiahe Biotech announced that due to devoting more time to other affairs, Zhou Xinhua decided to submit his resignation as executive director, effective from April 15, 2022
.
Zhou Xinhua also resigned from the position of president of the group
.
In early April, Sumitomo Pharma announced the appointment of Yilong Ling as the company's president, effective April 1, 2022
.
It is reported that Lingwei Yilong has 20 years of experience in the management of multinational pharmaceutical companies and is well versed in the Chinese pharmaceutical market
.
From 2019 to 2021, he served as President of Sumitomo Pharma Asia Pacific
.
Previously, he served as chairman and general manager of Astellas Pharmaceuticals (China)
.
On March 30, Shanghai Pharmaceuticals announced that Mr.
Gu Haoliang, the former vice president of the company, will no longer serve as vice president of the company from March 30, 2022 due to retirement; the former vice president, Ms.
Chen Jinzhu, has been transferred from March 2022.
From the 30th, he will no longer serve as the company's vice president and other positions, but still serve as the company's board secretary
.
On March 17, Medtronic announced the replacement of presidents of its diabetes, surgical robotics and cardiac rhythm management operating divisions.
The new appointments are: Que Dallara as executive vice president of diabetes and business president, and Mike Marinaro as president of surgical robotics , Dr.
Kweli Thompson was named President of Cardiac Rhythm Management
.
On February 18, Buchang Pharmaceutical announced that the board of directors received a written resignation report submitted by the company's director and vice president Li Weijun on February 18, 2022
.
The announcement shows that due to personal reasons, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors, and at the same time resigned from all positions held in the company's subsidiaries
.
It is worth mentioning that on January 6, Buchang Pharmaceutical announced that the board of directors received a written resignation report submitted by the vice president of the company, Mr.
Liu Luxiang, on January 6, 2022.
Mr.
Liu Luxiang also applied for his resignation as the vice president of the company due to personal reasons.
The position of president, after resignation, will not hold any position in the company
.
On February 16, YaoShi Technology announced that the company has recently appointed Dr.
Gu Zhentian as Senior Vice President of Quality and Registration, and is fully responsible for the quality management and registration management of YaoShi Technology
.
It is reported that Dr.
Gu has more than 20 years of R&D and management experience in the field of new drug R&D.
Before joining Yaoshi Technology, he served as the vice president of analytical R&D and quality control at Theravance in the United States, responsible for the development of innovative drug analytical methods, Research and development and management of verification, impurity identification and toxicity level certification, quality control and drug metabolism
.
On January 28, Watson Bio announced that the company's board of directors agreed to appoint Mr.
Dong Shaozhong as the company's vice president, responsible for the company's international business
.
It is reported that he served as the chairman of Dalian Hanxin Biopharmaceuticals, the quality authorized person, the chairman of Jiangsu Kanghuai Biotechnology, the director of the quality control department of the Institute of Medical Biology, Chinese Academy of Medical Sciences, the deputy director of the research institute, and the quality authorized person
.
On January 14, China Resources Sanjiu announced that in order to implement the three-year action plan for the reform of state-owned enterprises and strengthen the building of the board of directors and management team, the chairman of the company, Mr.
Qiu Huawei, nominated Mr.
Zhao Bingxiang as the company's president, and the term of office is the same as the term of the company's eighth board of directors.

.
On January 13, Lanfan Medical announced that it had recently received a written resignation report from the company's chairman and president Liu Wenjing on applying for no longer serving as president.
Liu Wenjing was out of the company's long-term strategic inheritance, incremental business development and the age of the company's management team.
Considering the echelon construction, the applicant no longer serves as the president
.
On January 10, Dong'e Ejiao sent two news of personnel changes in succession, one of which was Mr.
Gao Dengfeng's application to resign as the company's president and legal representative due to changes in job content
.
From the perspective of the industry, personnel changes in pharmaceutical executives have become the norm
.
With the changes in the pharmaceutical market environment, pharmaceutical companies are facing the pain of transformation.
Organizational structure adjustments and personnel changes have become frequent.
At the same time, the industry has an urgent demand for talents, which drives the acceleration of talent flow
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.